Methods for reducing viral load in HIV-1 infected patients
This invention provides a method of reducing viral load in an HIV-1-infected human subject which comprises administering to the subject an effective HIV-1 viral load reducing dose of a CCR5 receptor antagonist, such as a humanized antibody designated PRO 140 or an anti-CCR5 receptor monoclonal antibody, wherein the viral load reducing dose achieves an average maximum decrease of viral load in the subject of at least 1.83 log 10 to 2.5 log 10 at about ten days following administration of the CCR5 receptor antagonist and wherein the viral load reducing dose further achieves a mean viral load reduction of 1.7 log 10 at about nine days following administration of the CCR5 receptor antagonist.
1. A CCR5 receptor antagonist formulation consisting of a therapeutically effective single subcutaneous dose of a humanized monoclonal antibody designated PRO 140, or a fragment thereof, in an amount 5 mg/kg of body weight for an HIV-infected subject, wherein said formulation results in suppression of HIV-1 viral replication.
2. The CCR5 receptor antagonist formulation of claim 1 , wherein the PRO 140 comprises (i) two light chains, each light chain comprising the light chain variable (V L ) and constant (C L ) regions encoded by the plasmid designated pVK:HuPRO140-VK (ATCC Deposit Designation PTA-4097), and (ii) two heavy chains, each heavy chain comprising the heavy chain variable (V H ) and constant (C H ) regions encoded either by the plasmid designated pVg4:HuPR0140 HG2-VH (ATCC Deposit Designation PTA-4098) or by the plasmid designated pVg4:HuPR0140 (mut B+D+I)-VH (ATCC Deposit Designation PTA-4099), or a fragment thereof.
3. The CCR5 receptor antagonist formulation of claim 1 , wherein the therapeutically effective dose is about 324 mg.
4. The CCR5 receptor antagonist formulation of claim 1 , wherein the dose accounts for viral suppression for the HIV-infected subject for about seven days following the last dose.
5. The CCR5 receptor antagonist formulation of claim 1 , wherein the dosing regimen accounts for viral suppression for the HIV-infected subject for at least two weeks.
6. A therapeutic composition comprising a therapeutically effective single subcutaneous or intravenous dose of a CCR5 receptor antagonist in an amount of 5 mg/kg for an HIV-infected subject that results in suppression of HIV-1 viral replication, wherein the CCR5 receptor antagonist is a humanized monoclonal antibody designated PRO 140 or a fragment thereof, or a conjugate of said CCR5 receptor antagonist.
7. The therapeutic composition of claim 6 , wherein the CCR5 receptor antagonist comprises (a) a humanized monoclonal antibody designated PRO 140 which comprises (i) two light chains, each light chain comprising the light chain variable (V L ) and constant (C L ) regions encoded by the plasmid designated pVK:HuPR0140-VK (ATCC Deposit Designation PTA-4097), and (ii) two heavy chains, each heavy chain comprising the heavy chain variable (V H ) and constant (C H ) regions encoded either by the plasmid designated pVg4:HuPR0140 HG2-VH (ATCC Deposit Designation PTA-4098) or by the plasmid designated pVg4:HuPR0140 (mut B+D+I)-VH (ATCC Deposit Designation PTA-4099), or (b) a fragment thereof.
8. The CCR5 receptor antagonist formulation of claim 1 , wherein the therapeutically effective single subcutaneous dose does not result in an administration site reaction lasting more than two days.
9. The CCR5 receptor antagonist formulation of claim 6 , wherein the therapeutically effective single subcutaneous or intravenous dose does not result in an administration site reaction lasting more than two days.
10. The therapeutic composition of claim 6 , wherein the prolonged viral suppression is characterized by about a 1.83 log 10 decrease in HIV-1 RNA.
11. The CCR5 receptor antagonist formulation of claim 1 , wherein the prolonged viral suppression is characterized by about a 1.83 log 10 decrease in HIV-1 RNA.
12. A pharmaceutical composition comprising a CCR5 receptor antagonist subcutaneous formulation consisting of a therapeutically effective single subcutaneous dose of a humanized monoclonal antibody (mAb) designated PRO 140, or a fragment thereof, in an amount of 5 mg/kg of body weight for an HIV-1-infected subject, wherein said composition results in suppression of HIV-1 viral replication.